Procalcitonin and C-reactive protein as early markers of anastomotic leakage in intestinal resections for advanced ovarian cancer (EDMOCS).
anastomotic leakage
colorectal resection
ovarian cancer
Journal
Acta obstetricia et gynecologica Scandinavica
ISSN: 1600-0412
Titre abrégé: Acta Obstet Gynecol Scand
Pays: United States
ID NLM: 0370343
Informations de publication
Date de publication:
26 Mar 2024
26 Mar 2024
Historique:
revised:
29
02
2024
received:
05
11
2023
accepted:
02
03
2024
medline:
27
3
2024
pubmed:
27
3
2024
entrez:
27
3
2024
Statut:
aheadofprint
Résumé
Serum levels of procalcitonin and C-reactive protein (CRP) have been used to predict anastomotic leakage after colorectal surgery, but information is scarce in advanced ovarian cancer (AOC) surgery with bowel resection. This study aimed to assess the predictive value of procalcitonin and CRP in detecting anastomotic leakage after AOC surgery with bowel resection. The study also aimed to determine the optimal postoperative reference values and the best day for evaluating these markers. This prospective, observational and multicentric trial included 92 patients with AOC undergoing debulking surgery with bowel resection between 2017 and 2020 in 10 reference hospitals in Spain. Procalcitonin and CRP levels were measured at baseline and on postoperative days 1-6. Receiver operating characteristic analysis was performed to evaluate the predictive value of procalcitonin and CRP at each postoperative day. Sensitivity, specificity, positive and negative predictive values were calculated. Anastomotic leakage was detected in six patients (6.5%). Procalcitonin and CRP values were consistently higher in patients with anastomotic leakage at all postoperative days. The maximum area under the curve (AUC) for procalcitonin was observed at postoperative day 1 (AUC = 0.823) with a cutoff value of 3.8 ng/mL (83.3% sensitivity, 81.3% specificity). For CRP, the maximum AUC was found at postoperative day 3 (AUC = 0.833) with a cutoff level of 30.5 mg/dL (100% sensitivity, 80.4% specificity). Procalcitonin and C-reactive protein are potential biomarkers for early detection of anastomotic leakage after ovarian cancer surgery with bowel resection. Further prospective studies with a larger sample size are needed to confirm these findings.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Fundació Institut de Recerca Hospital Universitari Vall d'Hebron
Informations de copyright
© 2024 The Authors. Acta Obstetricia et Gynecologica Scandinavica published by John Wiley & Sons Ltd on behalf of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG).
Références
Coleridge SL, Bryant A, Kehoe S, Morrison J. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev. 2021;7:CD005343.
Jaeger W, Ackermann S, Kessler H, Katalinic A, Lang N. The effect of bowel resection on survival in advanced epithelial ovarian cancer. Gynecol Oncol. 2001;83:286‐291.
Stefanović A, Jeremić K, Kadija S, et al. Intestinal surgery in treatment of advanced ovarian cancer—review of our experience. Eur J Gynaecol Oncol. 2011;32:419‐422.
Peiretti M, Bristow RE, Zapardiel I, et al. Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi‐center analysis of surgical and oncological outcomes. Gynecol Oncol. 2012;126:220‐223.
Lago V, Fotopoulou C, Chiantera V, et al. Risk factors for anastomotic leakage after colorectal resection in ovarian cancer surgery: a multi‐centre study. Gynecol Oncol. 2019;153:549‐554.
Mourton SM, Temple LK, Abu‐Rustum NR, et al. Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol. 2005;99:608‐614.
Richardson DL, Mariani A, Cliby WA. Risk factors for anastomotic leak after recto‐sigmoid resection for ovarian cancer. Gynecol Oncol. 2006;103:667‐672.
Gruner M, Chambers LM, Yao M, et al. Anastomotic leak following interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in women with advanced epithelial ovarian cancer. Gynecol Oncol. 2021;162:645‐651.
Louis M, Johnston SA, Churilov L, Ma R, Christophi C, Weinberg L. Financial burden of postoperative complications following colonic resection: a systematic review. Medicine (Baltimore). 2021;100:e26546.
Wright JD, Herzog TJ, Neugut AI, et al. Effect of radical cytoreductive surgery on omission and delay of chemotherapy for advanced‐stage ovarian cancer. Obstet Gynecol. 2012;120:871‐881.
Gans SL, Atema JJ, van Dieren S, Groot Koerkamp B, Boermeester MA. Diagnostic value of C‐reactive protein to rule out infectious complications after major abdominal surgery: a systematic review and meta‐analysis. Int J Colorectal Dis. 2015;30:861‐873.
Cousin F, Ortega‐Deballon P, Bourredjem A, Doussot A, Giaccaglia V, Fournel I. Diagnostic accuracy of procalcitonin and C‐reactive protein for the early diagnosis of intra‐abdominal infection after elective colorectal surgery: a meta‐analysis. Ann Surg. 2016;264:252‐256.
Facy O, Paquette B, Orry D, et al. Diagnostic accuracy of inflammatory markers As early predictors of infection after elective colorectal surgery: results from the IMACORS study. Ann Surg. 2016;263:961‐966.
Giaccaglia V, Salvi PF, Antonelli MS, et al. Procalcitonin reveals early dehiscence in colorectal surgery: the PREDICS study. Ann Surg. 2016;263:967‐972.
Muñoz JL, Alvarez MO, Cuquerella V, et al. Procalcitonin and C‐reactive protein as early markers of anastomotic leak after laparoscopic colorectal surgery within an enhanced recovery after surgery (ERAS) program. Surg Endosc. 2018;32:4003‐4010.
Messias BA, Botelho RV, Saad SS, Mocchetti ER, Turke KC, Waisberg J. Serum C‐reactive protein is a useful marker to exclude anastomotic leakage after colorectal surgery. Sci Rep. 2020;10:1687.
Straatman J, Harmsen AM, Cuesta MA, Berkhof J, Jansma EP, van der Peet DL. Predictive value of C‐reactive protein for major complications after major abdominal surgery: a systematic review and pooled‐analysis. PLoS One. 2015;10:e0132995.
Agarwal R, Rajanbabu A, Nitu PV, Goel G, Madhusudanan L, Unnikrishnan UG. A prospective study evaluating the impact of implementing the ERAS protocol on patients undergoing surgery for advanced ovarian cancer. Int J Gynecol Cancer. 2019;29:605‐612.
Sánchez‐Iglesias JL, Carbonell‐Socias M, Pérez‐Benavente MA, et al. PROFAST: a randomised trial implementing enhanced recovery after surgery for highcomplexity advanced ovarian cancer surgery. Eur J Cancer. 2020;136:149‐158.
Sánchez‐Iglesias JL, Gómez‐Hidalgo NR, Pérez‐Benavente A, et al. Importance of enhanced recovery after surgery (ERAS) protocol compliance for length of stay in ovarian cancer surgery. Ann Surg Oncol. 2021;28(13):8979‐8986.
Mantovani A, Allavena P, Sica A, Balkwill F. Cancer‐related inflammation. Nature. 2008;454:436‐444.
Browning L, Patel MR, Horvath EB, Tawara K, Jorcyk CL. IL‐6 and ovarian cancer: inflammatory cytokines in promotion of metastasis. Cancer Manag Res. 2018;10:6685‐6693.
American College of Chest Physicians/Society of Critical Care Medicine. Consensus conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864‐874.
Watkins DT, Robertson CL. Water‐soluble radiocontrast material in the treatment of postoperative ileus. Am J Obstet Gynecol. 1985;152:450‐455.
Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien–Dindo classification of surgical complications: five‐year experience. Ann Surg. 2009;250:187‐196.
Sbrana A, Torchio M, Comolli G, Antonuzzo A, Danova M. Italian Network for Supportive Care in Oncology (NICSO). Use of procalcitonin in clinical oncology: a literature review. New Microbiol. 2016;39:174‐180.
Chaftari P, Qdaisat A, Chaftari AM, et al. Prognostic value of procalcitonin, C‐reactive protein, and lactate levels in emergency evaluation of cancer patients with suspected infection. Cancers (Basel). 2021;13:4087.
Smith M, Lara OD, O'Cearbhaill R, et al. Inflammatory markers in gynecologic oncology patients hospitalized with COVID‐19 infection. Gynecol Oncol. 2020;159:618‐622.
Su'a BU, Mikaere HL, Rahiri JL, Bissett IB, Hill AG. Systematic review of the role of biomarkers in diagnosing anastomotic leakage following colorectal surgery. Br J Surg. 2017;104:503‐512.
Llueca A, Serra A, Maiocchi K, et al. Predictive model for major complications after extensive abdominal surgery in primary advanced ovarian cancer. Int J Womens Health. 2019;11:61‐167.
Trabert B, Pinto L, Hartge P, et al. Pre‐diagnostic serum levels of inflammation markers and risk of ovarian cancer in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial. Gynecol Oncol. 2014;135:297‐304.
Lu Y, Huang S, Li P, et al. Prognostic evaluation of preoperative serum C‐reactive protein concentration in patients with epithelial ovarian cancer. Exp Ther Med. 2015;9:2003‐2007.
Yang D, Li H, Sun X, Yang S, Wang K, Liu Z. Clinical usefulness of high levels of C‐reactive protein for diagnosing epithelial ovarian cancer. Sci Rep. 2020;10:20056.
Mereu L, Dalprà F, Berlanda V, et al. Anastomotic leakage after colorectal surgery in ovarian cancer: drainage, stoma utility and risk factors. Cancer. 2022;14:6243.
Kim JH, Han WH, Lee DE, et al. Anastomotic leakage after resection of the rectosigmoid colon in primary ovarian cancer. J Ovarian Res. 2023;29(16):85.
Kryzauskas M, Bausys A, Dulskas A, et al. Comprehensive testing of colorectal anastomosis: results of prospective observational cohort study. Surg Endosc. 2022;36:6194‐6204.
de Nardi P, Elmore U, Maggi G, et al. Intraoperative angiography with indocyanine green to assess anastomosis perfusion in patients undergoing laparoscopic colorectal resection: results of a multicenter randomized controlled trial. Surg Endosc. 2020;34:53‐60.
Lago V, Montesinos‐Albert M, Segarra‐Vidal B, et al. ECO‐LEAK technique: early detection of colorectal anastomotic leakage by transvaginal ultrasound. Int J Gynecol Cancer. 2023;33(4):631‐632.
Llueca A, Serra A, Climent MT, et al. Postoperative intestinal fistula in primary advanced ovarian cancer surgery. Cancer Manag Res. 2021;13:13‐23.